apposters.com
Accent Therapeutics, Inc.
Edit

Accent Therapeutics, Inc.

http://www.accenttx.com/
Last activity: 23.01.2024
Active
Categories: BioTechChemicalDrugGrowthLifeScience
Leading the translation of RNA-modifying protein (RMP) biology into promising new therapies for cancer.
Followers
654
Followers
2.27K
Mentions
16
Location: United States, Massachusetts, Lexington
Employees: 11-50
Total raised: $178M
Founded date: 2017
Twitter
LinkedIn
Email

Investors 6

Funding Rounds 3

DateSeriesAmountInvestors
23.01.2024Series C$75M-
24.04.2020Series B$63M-
23.05.2018Series A$40M-

Mentions in press and media 16

DateTitleDescription
23.01.2024Accent Therapeutics Raises $75M in Series C FundingAccent Therapeutics, a Lexington, MA-based biopharmaceutical company focused on small molecule precision cancer therapies, raised $75M in Series C funding. The round was led by Mirae Asset Capital Life Science, with participation from other...
27.02.2023Accent Therapeutics upgrades to Xavo R3 for their small molecule Compound Management needsXavo, a leading provider of Software-as-a-Service for Biopharma R&D announces that Accent Therapeutics has gone live with the latest version of Xavo R3. BOSTON, MA, USA, February 27, 2023 /EINPresswire.com/ -- Xavo, a leading provider o...
29.04.2021ALDEYRA THERAPEUTICS, INC. Aldeyra Therapeutics, Inc. : Announces Pricing of $125 Million Public Offering of Common StockAldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced the...
27.04.2021ALDEYRA THERAPEUTICS, INC. Aldeyra Therapeutics, Inc. : Announces Proposed $125 Million Public Offering of Common StockAldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced tha...
01.07.2020June VC Funding: 65 startups raise over $2.2B with agtech, biotech leadingIt is summer for Boston startups indeed. More than 60 startups raised over $2 billion in venture funding in June. Chief among those were Duck Creek Technologies' $230 million round and Indigo Ag's $300 million Series F round. Venture capita...
24.04.2020Accent Therapeutics Completes $63M Series B FinancingAccent Therapeutics, a Lexington, MA-based biopharmaceutical company developing breakthrough treatments for cancer patients, completed a $63m Series B financing. The round was led by EcoR1 Capital with participation by GV, AbbVie Ventures, ...
24.04.2020Cancer Therapy Company Accent Therapeutics Raises $63 MillionBiopharmaceutical company Accent Therapeutics announced it has raised $63 million in Series B funding Biopharmaceutical company Accent Therapeutics announced it has raised $63 million in Series B funding led by EcoR1 Capital with participat...
23.04.2020Accent Therapeutics Announces $63 Million Series BLEXINGTON, Mass.--(BUSINESS WIRE)--Accent Therapeutics, a biopharmaceutical company developing breakthrough treatments for cancer patients, announced today that it has completed a $63 million Series B financing. The Series B was led by EcoR...
23.04.2020Accent Therapeutics nabs $63M for RNA cancer pushTwo years ago, Accent Therapeutics got off a $40 million series A to target RNA-modifying proteins in cancer; now, in the middle of a pandemic, it’s still managed to bring in a respectable $63 million second funding round. Sponsored by Agil...
23.04.2020It's not de­vel­op­ing drugs that bind to RNA, or mor­ph­ing RNA in­to a ther­a­peu­tic — this Cam­bridge start­up has scored $63M to work on RNA-mod­i­fy­ing pro­teinsFirst came the con­cept of epi­ge­net­ics, the study of chem­i­cal mod­i­fi­ca­tions made to the blue­print of life — DNA — to switch genes on or off. Then, sci­en­tists re­al­ized DNA’s cousin RNA could al­so be sub­ject to such chem­i­cal...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In